MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC

KRASG12C mutations occur in approximately 14% of patients with NSCLC. Adagrasib, an oral, selective KRASG12C inhibitor, was selected for favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and CNS penetration. Recently, based on data from KRYSTAL-1 (NCT03785249), a multicohort Phase 1/2 study evaluating adagrasib as monotherapy or in combination for patients with KRASG12C-mutated solid tumors, the FDA granted accelerated approval of adagrasib for patients with previously treated KRASG12C-mutated advanced/metastatic NSCLC.